TIDMPOLB

Poolbeg Pharma PLC

21 November 2023

Poolbeg Pharma plc

Immunomodulator II patent granted in Japan

Further enhancement of the patent portfolio

21 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the Japanese Patent Office has notified the Company of its official decision to grant Poolbeg's Immunomodulator II patent application.

The claims cover the pharmaceutical composition of POLB 001 for treating severe influenza in a hospitalised patient in combination with antiviral compounds, further strengthening the Company's robust intellectual property in the territory. The formal granted patent will be received in due course.

In addition, further to the Company's announcement on 20 September 2023 , it has received the fully granted patent for Immunomodulator I from the Japanese Patent Office.

Poolbeg has a worldwide licence for POLB 001 for all uses in humans and is developing a strong IP portfolio with patents in place, including Immunomodulator I and Immunomodulator II, covering the use of the class of p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of severe influenza and the use of POLB 001 for the treatment of hypercytokinaemia. The Company continues to seek broader patent protection for POLB 001 and p38 MAP kinase inhibitors in general around the treatment and prevention of severe influenza and hypercytokinemia, and has also filed patent applications, to expand its IP around POLB 001, to the use of p38 MAP kinase inhibitors alongside cancer immunotherapies, enhancing the value and attractiveness of POLB 001 to potential pharma partners.

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented: "The grant received from the Japanese Patent Office highlights the progress we are making in developing our patent portfolio. By strategically growing this exciting molecule's intellectual property portfolio, we aim to enhance its overall value for our partners. POLB 001 stands poised to make a substantial impact on global health and has tremendous potential to address unmet medical needs worldwide across multiple disease areas."

- Ends -

Enquiries

 
  Poolbeg Pharma Plc 
   Jeremy Skillington, CEO 
   Ian O'Connell, CFO                                            +44 (0) 207 183 1499 
  Cavendish Capital Markets Ltd (Nominated 
   Adviser & Joint Broker) 
   Geoff Nash, Charlie Beeson, Nigel 
   Birks, Harriet Ward (ECM)                                     +44 (0) 207 220 0500 
  Singer Capital Markets (Joint Broker) 
   Phil Davies, Sam Butcher                                       +44 (0) 207 496 3000 
  J&E Davy (Joint Broker) 
   Anthony Farrell, Niall Gilchrist                              +353 (0) 1 679 6363 
  Optimum Strategic Communications                               +44 (0) 208 078 4357 
   Nick Bastin, Hana Malik, Vici Rabbetts                         poolbeg@optimumcomms.com

About Poolbeg Pharma

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team and Board have been augmented with strong commercialisation expertise following the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.

Poolbeg's clinical programmes target large addressable markets across cancer immunotherapies, infectious disease, and an oral GLP-1 agonist for obesity and other metabolic conditions. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

   For more information, please go to  www.poolbegpharma.com  or follow us on   Twitter  and  LinkedIn @PoolbegPharma.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABMBRTMTATBMJ

(END) Dow Jones Newswires

November 21, 2023 02:00 ET (07:00 GMT)

Poolbeg Pharma (LSE:POLB)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Poolbeg Pharma.
Poolbeg Pharma (LSE:POLB)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Poolbeg Pharma.